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Since recog  nizing platelets as an important part in 
coagulation some 125 years ago, the scientiﬁ  c community 
has evaluated platelets as a key player between 
inﬂ   ammation and coagulation. Critically ill patients 
suﬀ  er from both inﬂ  ammation and impaired coagulation. 
Th  us, it is essential to learn more about the mutual 
inﬂ  uence between these two problems during intensive 
care therapy.
In this context, Sossdorf and colleagues [1] evaluated the 
impact of hydroxyethyl starch (HES) on thromb-
elastography and platelet receptors. Th  e authors investi-
gated 10% HES 200/0.5, 6% HES 130/0.4, and saline in an 
in vitro experiment with blood of healthy volunteers [1]. 
HESs are considered eﬀ  ective plasma volume expanders in 
clinical practice [2]. Adverse eﬀ  ects of HES adminis  tration 
on hemostasis have spurred ongoing research into the 
pathological mechanisms since these eﬀ  ects  are 
continually discussed as a serious limitation to the clinical 
use of HES [2]. Sossdorf and colleagues [1] could reveal a 
decreased maximum clot ﬁ  rmness in FIBTEM (rotation 
thromboelastometry [ROTEM®]-based measurement of 
the contribution of ﬁ  brinogen to the clot ﬁ  rmness) with a 
10% hemodilution by both tested HES solutions 
compared with saline. Other parameters of ROTEM® 
were aﬀ  ected by HES 200/0.5 but not by HES 130/0.4. A 
higher hemodilution of 40% showed comparable results 
for the two HESs. Accordingly, Innerhofer and colleagues 
[3] could demonstrate an inhibition of primary hemo-
stasis by HES 200/0.5 and gelatine.
Sossdorf and colleagues further demonstrated that a 
clinical reasonable hemodilution of 10% does not aﬀ  ect 
the tested platelet receptors with both HESs when 
compared with saline after activation with adenosine-di-
phosphate (ADP) or thrombin receptor agonist peptide 
(TRAP). Without the addition of an agonist, the authors 
detected a signiﬁ   cant 3% to 5% diﬀ  erence of platelet-
neutrophil conjugates after 10% hemodilution with 6% 
HES 130/0.4. In contrast, 10% HES 200/0.5 may adhere to 
the platelet surface and decrease ligand binding to the 
ﬁ  brinogen receptor with a hemodilution of 10% or more. 
Additionally, it was shown that the risk of bleeding is 
associated with synthetic colloids of higher molecular 
weight and higher degree of substitution [4].
A decreased P-selectin expression after activation with 
ADP in a 10% hemodilution with HES 130/0.4 is not 
necessarily in line with the proposed pro-inﬂ  ammatory 
action of HES. Yet the binding of P-selectin induces 
tissue factor expression on neutrophils [5], and in a 
positive feedback loop, neutrophils activate platelets as 
measured by P-selectin expression [6]. Moreover, plate-
lets are able to act via a P-selectin-independent pathway 
to activate neutrophils and to contribute to the formation 
of neutrophil extracellular traps [7]. It would be interesting 
to further investigate the TLR4 (Toll-like receptor 4) 
expression in patients with bacteremia and sepsis.
Th   e question therefore is whether there are important 
diﬀ  erent  eﬀ   ects between HES solutions on blood 
coagulation. HES solutions vary widely with respect to 
their physiochemical characteristics, hence the concen-
tration, molecular weight, degree of substitution, and C2/
C6 ratio account for diﬀ  erences in their pharmacokinetic 
and pharmacodynamic proﬁ   le [8]. With their in vitro
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Crystalloid and colloid solutions are used for 
resuscitation of the critically ill. One set of options, 
widely used today, are diff  erent preparations of 
hydroxyethyl starch (HES). However, the safety of HES 
regarding impairment of blood coagulation remains 
incompletely elucidated, a circumstance that limits 
its clinical use. Understanding mechanisms and 
potential diff  erences between low-molecular and 
low-substituted HES and other HES solutions seems 
clinically relevant.
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eﬀ  ects of diﬀ  erent HES solutions in this area. In vitro 
studies are limited because of the absence of the 
endothelium and compensatory mechanisms like 
buﬀ  ering and the control of pH and the lack of other 
electrolytes and metabolic degradation. Furthermore, it 
was shown that 130/0.42 dissolved in a balanced solution 
containing calcium was associated with fewer negative 
eﬀ   ects on thrombelastrography than HES 130/0.4 
dissolved in a solution without calcium [9]. Th  us,  more in 
vivo experiments seem to be important to increase the 
evidence of eﬀ  ects of various especially fast degradable 
HES preparations in patients undergoing surgery with 
major blood loss or in critically ill patients, especially 
those with sepsis. It seems of utmost importance to 
distinguish very clearly between diﬀ  erent clinical settings 
in order to identify underlying mechanisms of HES 
solutions on coagulation.
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